Stephen Saad’s wealth takes a hit as Aspen Pharmacare stock plunges, erasing $41 million
This downturn follows a $44 million gain in January, which had lifted his stake to R10.26 billion ($550.1 million).
Stephen Saad
Stephen Saad leads Africa’s largest drugmaker to $1.2 billion in half-year revenue
The growth was fueled by the successful integration of acquired products in Latin America.
Africa’s largest asset manager buys additional stake worth $67 million in Stephen Saad’s Aspen Pharmacare
With this latest transaction, PIC’s stake in Aspen is now worth nearly a billion dollars—R15.2 billion ($824.24 million).
South African pharma tycoon Stephen Saad’s Aspen stake rises above $550 million
With the recent rise in Aspen's stock price, the value of his holdings has crossed $550 million, marking a recovery after a challenging 2024.
Stephen Saad’s Aspen stake drops $99.7 million in 2024
This downturn is driven by a sustained decline in the market value of his holdings in Aspen Pharmacare, Africa's largest pharmaceutical company.
Stephen Saad’s stake in Africa’s largest pharmaceutical company sinks below $600 million
South African pharmaceutical tycoon Stephen Saad faces setback as Aspen Pharmacare shares decline.
Aspen’s 20-percent stock decline costs South African tycoon Stephen Saad nearly $160 million
Saad's wealth drops by nearly $160 million after Aspen Pharmacare's shares tumble 20.17 percent over the past 25 days on the JSE.
South African billionaire Stephen Saad loses $28 million in one week
This follows a gain of $32.2 million recorded between April 23 and May 1, when his stake increased from $654.18 million to $686.41 million.
South African billionaire Stephen Saad gains $32.2 million as Aspen shares soar
This increase underscores Saad’s significant influence in South Africa’s business landscape, elevating him among the top investors on the JSE.
South African billionaire Stephen Saad gains $21.1 million as Aspen shares soar
This rise in Saad’s stake underscores his pivotal role in South Africa’s business landscape, placing him among the top investors on the JSE.
South African billionaire Stephen Saad leads Aspen to record $1.1-billion revenue
Aspen anticipates a robust second half of 2024, supported by the launch of sterile manufacturing contracts and continued growth in its active pharmaceutical ingredients (API) business.
South African billionaire Stephen Saad gains $49 million as Aspen shares soar
This increase cements Saad’s position in the South African business scene, placing him among the leading investors on the JSE.
